The Mold Busters program, launched by the New York City Housing Authority after a 2013 class-action lawsuit, demonstrates how targeted housing fixes can drive measurable public health gains. New observational data presented at ATS 2026 estimates nearly 2,800 fewer asthma-related emergency department visits per year among public housing residents, equating to nine fewer visits per thousand people compared with demographically matched non-public housing controls. This large-scale analysis, while not an RCT, strengthens causal inference through dose-response patterns: buildings showing the sharpest drops in mold complaints experienced the steepest declines in exacerbations. Unlike smaller prior studies, the citywide scope highlights real-world scalability, yet it remains observational and thus vulnerable to unmeasured confounders such as concurrent policy changes or seasonal effects. The work builds on earlier evidence from a 2015 HUD-funded RCT in Boston public housing (n=129 homes) that linked comprehensive mold remediation to reduced asthma symptoms in children, and a 2022 longitudinal cohort study in Environmental Health Perspectives (n=3,200 low-income households) showing ventilation upgrades independently lowered respiratory hospitalizations by 18%. What original coverage overlooks is the program's potential to prevent incident asthma cases over decades rather than merely managing exacerbations, plus its underappreciated cost-effectiveness for addressing entrenched racial and income disparities in asthma burden. These findings position simple, evidence-based housing interventions as high-leverage tools for population-level equity, meriting expansion beyond New York.